MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA)

CUSIP: G4444C102

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Equity / COM
Total 13F shares
10,912,791
Share change
-487,298
Total reported value
$116,191,000
Price per share
$11.10
Number of holders
26
Value change
-$3,240,021
Number of buys
14
Number of sells
27

Quarterly Holders Quick Answers

What is CUSIP G4444C102?
CUSIP G4444C102 identifies HLXA - MOONLAKE IMMUNOTHERAPEUTICS - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) as of Q1 2022

As of 31 Mar 2022, MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA) was held by 26 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 10,912,791 shares. The largest 10 holders included Cormorant Asset Management, LP, FMR LLC, 683 Capital Management, LLC, BlackRock Inc., CITADEL ADVISORS LLC, STALEY CAPITAL ADVISERS INC, PRICE T ROWE ASSOCIATES INC /MD/, Beryl Capital Management LLC, Alpha Wave Global, LP, and Avidity Partners Management LP. This page lists 26 institutional shareholders reporting positions in this security for the Q1 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.